These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15486408)

  • 21. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.
    Benza RL; Barst RJ; Galie N; Frost A; Girgis RE; Highland KB; Strange C; Black CM; Badesch DB; Rubin L; Fleming TR; Naeije R
    Chest; 2008 Oct; 134(4):775-782. PubMed ID: 18625676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z
    Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.
    Frost AE; Langleben D; Oudiz R; Hill N; Horn E; McLaughlin V; Robbins IM; Shapiro S; Tapson VF; Zwicke D; DeMarco T; Schilz R; Rubenfire M; Barst RJ
    Vascul Pharmacol; 2005 Jun; 43(1):36-9. PubMed ID: 15890561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
    Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R
    Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitaxsentan in pulmonary arterial hypertension.
    Apostolopoulou SC; Rammos S
    Chest; 2003 May; 123(5):1772; author reply 1772-3. PubMed ID: 12740304
    [No Abstract]   [Full Text] [Related]  

  • 28. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension.
    Souza R; Martins BC; Jardim C; Cortopassi F; Fernandes CJ; Pulido T; Sandoval J
    Int J Clin Pract; 2007 Jan; 61(1):153-6. PubMed ID: 17229188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M; Galiè N
    J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ
    Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?
    Allanore Y
    Nat Clin Pract Rheumatol; 2008 May; 4(5):238-9. PubMed ID: 18382424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan.
    Ooi H; Colucci WS; Givertz MM
    Circulation; 2002 Sep; 106(13):1618-21. PubMed ID: 12270852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
    Rondelet B; Kerbaul F; Vivian GF; Hubloue I; Huez S; Fesler P; Remmelink M; Brimiouille S; Salmon I; Naeije R
    Pediatr Res; 2007 Mar; 61(3):284-8. PubMed ID: 17314684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin receptor blockers in cardiovascular disease.
    Rich S; McLaughlin VV
    Circulation; 2003 Nov; 108(18):2184-90. PubMed ID: 14597580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.